Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Here's a recent video podcast I just did on the publication just out in Lancet Oncology, describing a randomized phase II study led by my friend Pasi Janne, from Dana Farber Cancer Institute in Boston.
[powerpress]
We've touched on this study before, but it's promising enough for the field of lung cancer that it should be covered as the publication comes out, especially since KRAS mutations are actually the most common molecular defect we see in NSCLC, and yet we haven't had an actual treatment to offer such patients in the past. Let's hope this work leads that to change soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Hi James Anthony, I'm so sorry you are going through this and so very young. It' s true that some people benefit for years with chemo and targeted therapies. With the...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.